结直肠癌筛查:粪便免疫化学检测、乙状结肠镜或结肠镜的临床实践指南
该指南针对50-79岁无症状、未筛查过且预期寿命≥15年的成人,基于15年随访证据和微模拟模型,建议15年结直肠癌风险低于3%者不筛查(弱推荐),高于3%者选择每年FIT、每两年FIT、单次乙状结肠镜或单次结肠镜(弱推荐)。证据确定性低,需共享决策。
要点
- 适用人群:50-79岁、无症状、未筛查过、预期寿命≥15年。
- 15年结直肠癌风险低于3%者建议不筛查(弱推荐)。
- 风险高于3%者建议四种筛查方案之一(弱推荐),需共享决策。
核心结论
- 对于50-79岁无症状未筛查成人,15年结直肠癌风险低于3%建议不筛查,高于3%建议四种筛查方案之一,均为弱推荐。
研究设计与样本
- 由患者、临床医生、内容专家和方法学家组成的指南小组采用GRADE方法制定,基于链接的系统综述和微模拟模型评估15年筛查获益与危害。
主要发现
- 15年获益、负担和危害的证据确定性低,四种筛查方案结直肠癌死亡率降低相似。
- 每两年FIT对15年癌症发病率可能无影响或影响很小;每年FIT、乙状结肠镜和结肠镜可能降低发病率,但FIT的发病率降低幅度小于乙状结肠镜和结肠镜。
- 筛查相关的严重胃肠道和心血管不良事件罕见。
- 获益大小取决于个体风险,而危害和负担与癌症风险关联较弱。
关键数值与推荐
- 15年结直肠癌风险低于3%:建议不筛查(弱推荐)。
- 15年结直肠癌风险高于3%:建议每年FIT、每两年FIT、单次乙状结肠镜或单次结肠镜(弱推荐)。
临床怎么用
- 临床应评估个体15年结直肠癌风险,低于3%者可讨论不筛查,高于3%者应共享决策选择筛查方案。
局限性
- 15年获益、负担和危害的证据确定性低,存在 substantial 不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLINICAL QUESTION: Recent 15-year updates of sigmoidoscopy screening trials provide new evidence on the effectiveness of colorectal cancer screening. Prompted by the new evidence, we asked: "Does colorectal cancer screening make an important difference to health outcomes in individuals initiating screening at age 50 to 79? And which screening option is best?" CURRENT PRACTICE: Numerous guidelines recommend screening, but vary on recommended test, age and screening frequency. This guideline looks at the evidence and makes recommendations on screening for four screening options: faecal immunochemical test (FIT) every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy. RECOMMENDATIONS: These recommendations apply to adults aged 50-79 years with no prior screening, no symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 15-year colorectal cancer risk below 3%, we suggest no screening (weak recommendation). For individuals with an estimated 15-year risk above 3%, we suggest screening with one of the four screening options: FIT every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy (weak recommendation). With our guidance we publish the linked research, a graphic of the absolute harms and benefits, a clear description of how we reached our value judgments, and linked decision aids. HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, clinicians, content experts and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. A linked systematic review of colorectal cancer screening trials and microsimulation modelling were performed to inform the panel of 15-year screening benefits and harms. The panel also reviewed each screening option's practical issues and burdens. Based on their own experience, the panel estimated the magnitude of benefit typical members of the population would value to opt for screening and used the benefit thresholds to inform their recommendations. THE EVIDENCE: Overall there was substantial uncertainty (low certainty evidence) regarding the 15-year benefits, burdens and harms of screening. Best estimates suggested that all four screening options resulted in similar colorectal cancer mortality reductions. FIT every two years may have little or no effect on cancer incidence over 15 years, while FIT every year, sigmoidoscopy, and colonoscopy may reduce cancer incidence, although for FIT the incidence reduction is small compared with sigmoidoscopy and colonoscopy. Screening related serious gastrointestinal and cardiovascular adverse events are rare. The magnitude of the benefits is dependent on the individual risk, while harms and burdens are less strongly associated with cancer risk. UNDERSTANDING THE RECOMMENDATION: Based on benefits, harms, and burdens of screening, the panel inferred that most informed individuals with a 15-year risk of colorectal cancer of 3% or higher are likely to choose screening, and most individuals with a risk of below 3% are likely to decline screening. Given varying values and preferences, optimal care will require shared decision making.
引用
- Helsingen LM, Vandvik PO, Jodal HC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019. PMID: 31578196. doi:10.1136/bmj.l5515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。